A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Imlunestrant
DRUG: Goserelin
DRUG: Tamoxifen 20 mg

Sponsor

Eli Lilly and Company